FDA Approves Capvaxiveâ„¢: A Revolutionary Vaccine for Pneumonia and Invasive Disease
CAPVAXIVE (V116) is an FDA-approved vaccine for adults to combat invasive pneumococcal disease (IPD). It targets the serotypes responsible...
CAPVAXIVE (V116) is an FDA-approved vaccine for adults to combat invasive pneumococcal disease (IPD). It targets the serotypes responsible...
Regulatory reliance in regulatory frameworks refers to the practice where regulatory authorities use assessments conducted by other agencies to...
Remepy, a pioneer in “hybrid drugs,” has secured $15 million in funding, led by NFX and supported by several...
Merck announced that the European Commission (EC) has approved KEYTRUDA, its anti-PD-1 therapy, for use in combination with platinum-containing...
At the 2023 Medidata NEXT conference, prominent figures like Michelle Hartman from South Broward Research, Adam Kinsey from Merck,...